Clinical Trials Directory

Trials / Unknown

UnknownNCT06226519

Integrated PET/MRI and Germline Variants to Differentiate Brain Tumopr Recurrence From Iatrogenicchanges in Children

Status
Unknown
Phase
Study type
Observational
Enrollment
60 (estimated)
Sponsor
IRCCS San Raffaele · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers

Summary

Nuclear magnetic resonance imaging (NMR) is used in pediatric brain tumors for purposes of diagnosis, evaluation of response to treatments, and monitoring of patients in follow-up. Through conventional imaging techniques it remains difficult to differentiate tumor recurrence from pseudo-progression or other iatrogenic changes after radiotherapy or chemotherapy, but it remains a relevant and essential clinical need for patient management.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TEST11C-MET-PET/RMN60 children and/or adolescents (≤18 years) with a diagnosis of brain tumor (medulloblastoma, other embryonal tumors or high-grade gliomas), who have followed the contemporary adjuvant therapy protocol of post-surgical chemo and radiotherapy and completed radiotherapy for at least 6 months will undergo a brain MET-PET/MRI.

Timeline

Start date
2020-05-13
Primary completion
2024-05-13
Completion
2024-05-13
First posted
2024-01-26
Last updated
2024-01-26

Locations

1 site across 1 country: Italy

Source: ClinicalTrials.gov record NCT06226519. Inclusion in this directory is not an endorsement.